; table of contents. Sec. 2. Findings. Sec. 3. Continuing support for research on endemic orphan fungal diseases. Sec. 4. Endemic orphan fungal disease Federal-State match pilot program. Sec. 5. FDA guidance for industry on development of diagnostics and antifungal drugs and vaccines for Valley Fever. Sec. 6. Including antifungal biological products as qualified infectious disease products. Sec. 7. Priority review to encourage treatments for endemic orphan fungal diseases. Sec. 8. Including antifungal products in the CARB–X program. Sec. 9. Blockchain pilot program for hospital data security for coccidioidomycosis research. 2. Findings Congress finds the following: (1) Worldwide fungal infections, such as candidiasis, cryptococcosis, and aspergillosis, often pose fatal opportunistic threats to immunologically impaired persons. (2) Endemic fungal infections, such as histoplasmosis, coccidioidomycosis, and blastomycosis, occur in certain geographic regions worldwide, including in the United States, and are acquired through exposure to the environment. (3) Because the endemic mycoses referred to in paragraph (2) are regional, such endemic mycoses do not receive the same amount of resources as mycoses of worldwide distribution, even though within the regions in which they are endemic such strains pose significant public health threats. (4) Coccidioidomycosis, also known as Valley Fever, is a fungal infection acquired by the inhalation of spores of certain fungi primarily found in the soil endemic to the American Southwest, including in Arizona, California, Nevada, New Mexico, Texas, Utah, and Washington. (5) According to the Morbidity and Mortality Weekly Report issued by the Centers for Disease Control and Prevention and dated August 11, 2017— (A) 97 percent of the all reported cases of Valley Fever occurred in California and Arizona